Advertisement

Topics

Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep?

06:50 EDT 16 Aug 2017 | Medscape

Though they have received a lot of hype as the heir apparent in lung cancer therapy, the early signals on combining immunotherapies are not reassuring, cautions Dr Jack West.
Medscape Oncology

Original Article: Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep?

NEXT ARTICLE

More From BioPortfolio on "Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...